DexComXSWX:DXCM 90 Buyback Yield % is -0.10 as of Jun. 26, 2026. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review. Among 346 Medical Devices & Instruments companies, DexCom ranks better than 56.07% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for DexCom's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:DXCM vs GEHC, STE, ZBH: Buyback Yield % Comparison
For the Medical Devices subindustry, DexCom's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where DexCom's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexCom (XSWX:DXCM) has a Buyback Yield % of -0.10 as of Jun. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DexCom and its competitors. According to the industry distribution chart, DexCom ranks #152 out of 346 companies in the Medical Devices & Instruments industry, placing it in the top 43.9%.
Is DexCom's Buyback Yield % too high?
DexCom's current Buyback Yield % is -0.10. Based on the distribution chart, DexCom ranks #152 out of 346 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's Buyback Yield % compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #152 out of 346 companies for Buyback Yield %. This puts DexCom in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DexCom and its competitors. DexCom's current Buyback Yield % is -0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current Buyback Yield % of -0.10. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current Buyback Yield % is -0.10. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current Buyback Yield % is -0.10 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (XSWX:DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.
Key valuation signals for XSWX:DXCM:
Buyback Yield %: -0.10
GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for XSWX:DXCM
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DXCM has been successfully added to your 
